Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 1, 2009, Pages 77-83

  Bergstrand, M ^a   Soderlind E ^b   Weitschies, W ^c   Karlsson, M O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FELODIPINE;

ARTICLE; CHEMICAL PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG RELEASE; DRUG TRANSPORT; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL TRACT; HUMAN; IN VIVO STUDY; LABORATORY TEST; MAGNETIC MARKER MONITORING; MAGNETISM; MODEL; NORMAL HUMAN; PRIORITY JOURNAL; STOMACH; TABLET FORMULATION;

ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; GASTROINTESTINAL TRANSIT; HUMANS; MAGNETICS; MARKOV CHAINS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; TABLETS;

EID: 67650581753     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.43     Document Type: Article

References (27)

1. Weitschies, W., Kosch, O., Monnikes, H. & Trahms, L. Magnetic Marker Monitoring: an application of biomagnetic measurement instrumentation and principles for the determination of the gastrointestinal behavior of magnetically marked solid dosage forms. Adv. Drug Deliv. Rev. 57, 1210-1222 (2005).
2. Weitschies, W. et al. Impact of the intragastric location of extended release tablets on food interactions. J. Control Release 108, 375-385 (2005).
3. Weitschies, W. et al. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur. J. Pharm. Biopharm. 70, 641-648 (2008).
4. Podczeck, F., Course, N.J. & Newton, J.M. Determination of the gastric emptying of solid dosage forms using gamma-scintigraphy: a problem of image timing and mathematical analysis. Eur. J. Nucl. Med. 26, 373-378 (1999).
5. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
6. Miller, R. et al. How modeling and simulation have enhanced decision making in new drug development. J. Pharmacokinet. Pharmacodyn. 32, 185-197 (2005).
7. Powell, J.R. & Gobburu, J.V. Pharmacometrics at FDA: evolution and impact on decisions. Clin. Pharmacol. Ther. 82, 97-102 (2007).
8. Sheiner, L.B. Learning versus confrming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997).
9. Aarons, L. et al. Role of modelling and simulation in Phase I drug development. Eur. J. Pharm. Sci. 13, 115-122 (2001).
10. Haruta, S. et al. Evaluation of absorption kinetics of orally administered theophylline in rats based on gastrointestinal transit monitoring by gamma scintigraphy. J. Pharm. Sci. 90, 464-473 (2001).
11. Iavarone, L. et al. A population PK model to evaluate variability in oral absorption using gamma scintigraphy. PAGE 17 (2008) Abstr 1319 .
12. Gaynor, C., Dunne, A. & Davis, J. A comparison of the prediction accuracy of two IVIVC modelling techniques. J. Pharm. Sci. 97, 3422-3432 (2008).
13. Gaynor, C., Dunne, A. & Davis, J. A diferential equations approach to in vitro-in vivo correlation modelling in NONMEM. PAGE 17 (2008) Abstr 1267 .
14. Buchwald, P. Direct, diferential-equation-based in-vitro-in-vivo correlation (IVIVC) method. J. Pharm. Pharmacol. 55, 495-504 (2003).
15. Edgar, B. et al. Felodipine kinetics in healthy men. Clin. Pharmacol. Ther. 38, 205-211 (1985).
16. Nyberg, L., Mansson, W., Abrahamsson, B., Seidegard, J. & Borga, O. A convenient method for local drug administration at predefned sites in the entire gastrointestinal tract: experiences from 13 phase I studies. Eur. J. Pharm. Sci. 30, 432-440 (2007).
17. Petri, N., Borga, O., Nyberg, L., Hedeland, M., Bondesson, U. & Lennernas, H. Efect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. Int. J. Clin. Pharmacol. Ther. 44, 71-79 (2006).
18. Plendil extended-release tablets [FDA label]. (2004).
19. Abrahamsson, B. et al. Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets. Pharm. Res. 10, 709-714 (1993).
20. Gisleskog, P.O., Karlsson, M.O. & Beal, S.L. Use of prior information to stabilize a population data analysis. J. Pharmacokinet. Pharmacodyn. 29, 473-505 (2002).
21. Edgar, B., Hofmann, K.J., Lundborg, P. , Regardh, C.G., Ronn, O. & Weidolf, L. Absorption, distribution and elimination of felodipine in man. Drugs 29 (suppl 2), 9-15 (1985).
22. Beal, S.L., Sheiner, L.B. & Boeckmann, A.J. NONMEM Users Guides (1989-2006) (Icon Development Solutions, Ellicott City, MD).
23. Jonsson, E.N. & Karlsson, M.O. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).
24. Edgar, B., Regardh, C.G., Attman, P.O., Aurell, M., Herlitz, H. & Johnsson, G. Pharmacokinetics of felodipine in patients with impaired renal function. Br. J. Clin. Pharmacol. 27, 67-74 (1989).
25. Gordi, T., Xie, R., Huong, N.V., Huong, D.X., Karlsson, M.O. & Ashton, M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable frst-pass hepatic extraction. Br. J. Clin. Pharmacol. 59, 189-198 (2005).
26. Holford, N.H. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30, 329-332 (1996).
27. Lindbom, L., Pihlgren, P. & Jonsson, E.N. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed efect modeling using NONMEM. Comput. Methods Programs Biomed. 79, 241-257 (2005).